The HSP70 and HSP90 chaperones work together to target certain client proteins, including EGFR/HER1 for degradation by the ubiquitin-proteasome system, and inhibitory agents targeting HSPs are one of the potential approaches for cancer therapeutics today [49,50]. The gene discussed is EGFR; the disease is cancer.